Plandai Biotechnology Inc (OTCMKTS:PLPL), better known for producing Phytofare Catechin complex, announced that it has decided to expand its sales agreement with USN. As part of the new agreement, Plandai will now be able to sell its flagship Phytofare in new locations, including European Union.
Management Call
The senior management team of Plandai Biotechnology is excited to announce this news and hopes that it will help the company fulfill demand in different markets. According to Callum Cottrell-Duffield, VP – Sales & Marketing, Plandai, it’s great to expand company’s sales network in European Union. It’s a dream come true alike situation that would never come true without USN’s help. With this expansion, Plandai believes that the sales of Phytofare will touch all new levels down the line.
USN is a market leader in wellness and sports nutrition and clearly understands what people need to stay fit and healthy. With USN’s support, Plandai is confident that it will reach to the right set of customers within the least possible time. Adding to Duffield’s comment, USN’s spokeswoman Irma Botes said that the demand for Plandai’s product has been increasing at a fast pace. As a partner, it’s the primary duty of USN to make sure that Phytofare reaches to the all the customers in the least possible time.
Meanwhile Vyta Corp (OTCMKTS:BLAB) announced some time back that it had completed the acquisition of Ribbon Naturals Corporation in an effective way. It was purely a stock based transaction. Both the companies hope that this transaction would help them develop, market and sell their products in an effective way.
Another pharma company named Ritter Pharmaceuticals Inc (NASDAQ:RTTR) has announced that it will be present at the well-known 3rd Microbiome R&D Business Collaboration Forum taking place on September 10 and 11 in San Diego. Company’s CEO Michael Step is there to represent the company and talk about its flagship product RP-G28 in front of the investors community.
